ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Wei Guang Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2946-7897; OpenAlex author ID A5100604775. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper

Papers 2

Augmenting the therapeutic efficacy of adenosine against pancreatic cancer by switching the Akt/p21-dependent senescence to apoptosis. Co-author DOI 10.1016/j.ebiom.2019.08.068 ↗
A new endoscopic ultrasonography image processing method to evaluate the prognosis for pancreatic cancer treated with interstitial brachytherapy. Co-author DOI 10.3748/wjg.v19.i38.6479 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Jie Liu · 1 shared paper, 2019 · strength 0.08
- Paper Augmenting the therapeutic efficacy of adenosine against pancreatic cancer by switching the Akt/p21-dependent senescenc… DOI 10.1016/j.ebiom.2019.08.068 ↗
Qi Zhang · 1 shared paper, 2019 · strength 0.08
- Paper Augmenting the therapeutic efficacy of adenosine against pancreatic cancer by switching the Akt/p21-dependent senescenc… DOI 10.1016/j.ebiom.2019.08.068 ↗
Dongqin Yang · 1 shared paper, 2019 · strength 0.08
- Paper Augmenting the therapeutic efficacy of adenosine against pancreatic cancer by switching the Akt/p21-dependent senescenc… DOI 10.1016/j.ebiom.2019.08.068 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.